Positive progress in anti-infectives Xellia Pharmaceuticals specialises in the development and manufacture of advanced, anti-infective treatments, which are used against serious and often life-threatening bacterial infections. The company’s major investment programme in new facilities in Europe and North America underscores its growing success and innovative product pipeline, which is set to significantly enhance global patient care and convenience. Philip Yorke reports.
146 Industry Europe
